Deqiang Wang1, Ning Wang2, Xiaoqin Li1, Xiaofeng Chen3, Bo Shen4, Dongqin Zhu5, Liuqing Zhu5, Yaping Xu6, Yangyang Yu7, Yongqian Shu8. 1. Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China. 2. Department of Oncology, The PLA Rocket Force Characteristic Medical Center, Beijing, China. 3. Department of Medical Oncology, Jiangsu Province Hospital, Nanjing, China. 4. Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. 5. Nanjing Geneseeq Technology Inc, Nanjing, China. 6. Geneplus-Beijing Institute, Beijing, China. 7. The Medical Department, 3D Medicines Inc, Shanghai, China. 8. Department of Medical Oncology, Jiangsu Province Hospital, Nanjing, China. shuyongqian@csco.org.cn.
Abstract
BACKGROUND: Tumor mutation burden (TMB) predicts immunotherapy efficacy in solid tumors. However, the biomarker role of TMB is still conflicting in resected tumors. We aimed to examine the association of TMB with prognosis and postoperative chemotherapy (CT) or radiochemotherapy (RCT) efficacy in resected gastric cancer (GC). METHODS: Whole-exome sequencing (WES) was performed in 73 resected GC specimens. Validation cohorts included 352 patients from The Cancer Genome Atlas (TCGA) and 222 patients from the Asian Cancer Research Group (ACRG). Immune infiltration and hypoxia were evaluated by transcriptome data and immunohistochemistry assay. RESULTS: TMB-high GC had favorable overall survival (OS) and disease-free survival (DFS), but the OS and DFS benefits with postoperative CT/RCT were more pronounced in TMB-low GC. These findings were consistent among all three cohorts and were maintained in the pooled cohort. Stratified by stages in the pooled cohort, stage III GC benefited from postoperative CT/RCT regardless of TMB level while stage Ib/II GC benefited from postoperative CT/RCT in TMB-low but not in TMB-high subgroup. TMB positively correlated with immune infiltration which was characterized by NK cell rather than CD8 + T cell enrichment. TMB-high GC was more hypoxic than TMB-low GC, and TMB-high stage Ib/II GC was the most hypoxic. CONCLUSIONS: High TMB may predict favorable prognosis in resected GC but poor response to postoperative CT/RCT in stage Ib/II subgroup, which may be determined by TMB-associated immune infiltration and hypoxia, respectively.
BACKGROUND: Tumor mutation burden (TMB) predicts immunotherapy efficacy in solid tumors. However, the biomarker role of TMB is still conflicting in resected tumors. We aimed to examine the association of TMB with prognosis and postoperative chemotherapy (CT) or radiochemotherapy (RCT) efficacy in resected gastric cancer (GC). METHODS: Whole-exome sequencing (WES) was performed in 73 resected GC specimens. Validation cohorts included 352 patients from The Cancer Genome Atlas (TCGA) and 222 patients from the Asian Cancer Research Group (ACRG). Immune infiltration and hypoxia were evaluated by transcriptome data and immunohistochemistry assay. RESULTS: TMB-high GC had favorable overall survival (OS) and disease-free survival (DFS), but the OS and DFS benefits with postoperative CT/RCT were more pronounced in TMB-low GC. These findings were consistent among all three cohorts and were maintained in the pooled cohort. Stratified by stages in the pooled cohort, stage III GC benefited from postoperative CT/RCT regardless of TMB level while stage Ib/II GC benefited from postoperative CT/RCT in TMB-low but not in TMB-high subgroup. TMB positively correlated with immune infiltration which was characterized by NK cell rather than CD8 + T cell enrichment. TMB-high GC was more hypoxic than TMB-low GC, and TMB-high stage Ib/II GC was the most hypoxic. CONCLUSIONS: High TMB may predict favorable prognosis in resected GC but poor response to postoperative CT/RCT in stage Ib/II subgroup, which may be determined by TMB-associated immune infiltration and hypoxia, respectively.
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Hui Yu; Zhengming Chen; Karla V Ballman; Mark A Watson; Ramaswamy Govindan; Irena Lanc; David G Beer; Raphael Bueno; Lucian R Chirieac; Michael Herman Chui; Guoan Chen; Wilbur A Franklin; David R Gandara; Carlo Genova; Kristine A Brovsky; Mary-Beth M Joshi; Daniel T Merrick; William G Richards; Christopher J Rivard; David H Harpole; Ming-Sound Tsao; Adrie van Bokhoven; Frances A Shepherd; Fred R Hirsch Journal: J Thorac Oncol Date: 2018-09-22 Impact factor: 15.609